Stock Traders Buy Large Volume 10x Genomic Puts (NASDAQ: TXG)
10x Genomics, Inc. (NASDAQ: TXG) saw unusually large options trading on Friday. Investors bought 4,599 put options on the stock. This is an 881% increase over the average daily volume of 469 puts.
Separately, insider Benjamin J. Hindson sold 351 shares of the company in a transaction dated Monday, November 22. The stock was sold for an average price of $ 148.38, for a total trade of $ 52,081.38. The transaction has been disclosed in a legal file with the Securities & Exchange Commission, which is available through this link. Additionally, insider Benjamin J. Hindson sold 41,666 shares of the company in a trade dated Monday, November 1. The stock was sold for an average price of $ 163.58, for a total value of $ 6,815,724.28. Disclosure of this sale can be found here. Insiders have sold 275,402 shares of the company valued at $ 42,024,650 in the past 90 days. Company insiders own 11.57% of the company’s shares.
Hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. BlackRock Inc. increased its holdings of 10x Genomics shares by 42.2% during the 2nd quarter. BlackRock Inc. now owns 7,549,175 shares of the company valued at $ 1,478,280,000 after acquiring an additional 2,242,036 shares during the last quarter. Vigilant Capital Management LLC increased its stake in 10x Genomics by 2.4% during the 3rd quarter. Vigilant Capital Management LLC now owns 63,488 shares of the company valued at $ 9,243,000 after purchasing an additional 1,461 shares during the period. Bank of Montreal Can increased its holdings in 10x Genomics by 2.4% in the second quarter. Bank of Montreal Can now owns 37,839 shares of the company valued at $ 7,628,000 after purchasing an additional 889 shares during the period. Jasper Ridge Partners LP increased its holdings in 10x Genomics by 12.2% during the second quarter. Jasper Ridge Partners LP now owns 23,433 shares of the company valued at $ 4,589,000 after purchasing an additional 2,544 shares during the period. Finally, Tributary Capital Management LLC acquired a new position in 10x Genomics during the 3rd quarter valued at approximately $ 830,000. 77.50% of the shares are currently held by institutional investors.
Several research analysts recently commented on the company. Zacks Investment Research reduced 10x Genomics from a “buy” rating to a “keep” rating in a research report released on Friday, October 22. National Bank Financial began covering 10x Genomics in a research report on Thursday, September 16. They set a “sector performance” rating and a price target of $ 24.00 for the company. Morgan Stanley lowered its 10x Genomics price target from $ 215.00 to $ 205.00 and set an “overweight” rating on the stock in a research note on Thursday, November 4. Finally, Bank of America downgraded 10x Genomics from a “buy” rating to a “neutral” rating and set a price target of $ 180.00 for the share. in a research note on Tuesday, September 14. Three equity research analysts rated the stock with a conservation rating and five gave the stock a buy rating. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $ 169.29.
10x Genomics stock traded down $ 2.98 at midday on Friday, reaching $ 127.79. 600,521 shares of the company were traded, for an average volume of 663,524. The company has a fifty-day simple moving average of $ 149.88 and a 200-day simple moving average of $ 163.35. 10x Genomics has a 12-month low of $ 125.60 and a 12-month high of $ 208.99. The company has a market cap of $ 14.28 billion, a PE ratio of -30.21 and a beta of 1.38.
10x Genomics (NASDAQ: TXG) last released its results on Wednesday, November 3. The company reported ($ 0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($ 0.18) by $ 0.03. The company posted revenue of $ 125.30 million for the quarter, compared to a consensus estimate of $ 124.07 million. 10x Genomics recorded a negative return on equity of 6.30% and a negative net margin of 99.17%. In the same quarter of last year, the company posted ($ 0.33) EPS. As a group, research analysts expect 10x Genomics to post EPS of -0.42 for the current year.
About 10x the genomics
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables and software for the analysis of biological systems in North America, Europe, Middle East, Africa, China and Asia-Pacific. The company provides chrome and chrome connection instruments, microfluidic chips, slides, reagents and other consumables.
See also: What should I know about analyst ratings?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in 10x Genomics now?
Before you consider 10x genomics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the top five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes a hold of … and 10x Genomics was not on the list.
While 10x Genomics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here